- Home
- NUWE vs AZTR Comparison
NUWE vs AZTR Comparison
Compare NUWE & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUWE
- AZTR
- Stock Information
- Founded
- NUWE 1999
- AZTR 2014
- Country
- NUWE United States
- AZTR United States
- Employees
- NUWE N/A
- AZTR N/A
- Industry
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- AZTR Biotechnology: Pharmaceutical Preparations
- Sector
- NUWE Health Care
- AZTR Health Care
- Exchange
- NUWE Nasdaq
- AZTR Nasdaq
- Market Cap
- NUWE 3.9M
- AZTR 4.2M
- IPO Year
- NUWE N/A
- AZTR 2023
- Fundamental
- Price
- NUWE $3.86
- AZTR $0.73
- Analyst Decision
- NUWE
- AZTR Strong Buy
- Analyst Count
- NUWE 0
- AZTR 1
- Target Price
- NUWE N/A
- AZTR $4.00
- AVG Volume (30 Days)
- NUWE 325.0K
- AZTR 158.2K
- Earning Date
- NUWE 11-10-2025
- AZTR 11-11-2025
- Dividend Yield
- NUWE N/A
- AZTR N/A
- EPS Growth
- NUWE N/A
- AZTR N/A
- EPS
- NUWE N/A
- AZTR N/A
- Revenue
- NUWE $8,318,000.00
- AZTR N/A
- Revenue This Year
- NUWE $6.53
- AZTR N/A
- Revenue Next Year
- NUWE $51.63
- AZTR N/A
- P/E Ratio
- NUWE N/A
- AZTR N/A
- Revenue Growth
- NUWE N/A
- AZTR N/A
- 52 Week Low
- NUWE $3.09
- AZTR $0.68
- 52 Week High
- NUWE $175.98
- AZTR $4.33
- Technical
- Relative Strength Index (RSI)
- NUWE 45.84
- AZTR 51.80
- Support Level
- NUWE $3.09
- AZTR $0.72
- Resistance Level
- NUWE $3.60
- AZTR $0.79
- Average True Range (ATR)
- NUWE 0.21
- AZTR 0.04
- MACD
- NUWE 0.11
- AZTR -0.01
- Stochastic Oscillator
- NUWE 90.51
- AZTR 51.07
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
About AZTR Azitra Inc
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.